Advances in structural and molecular neuroimaging in Alzheimer's disease

Grants

Funding Acknowledgements

Core funding for the AIBL study was provided by the CSIRO and was matched by contributions from the study partners (see http://www.aibl.csiro.au). The study also receives support from the National Health and Medical Research Council and the Dementia Collaborative Research Centres program (DCRC2). Pfizer International has contributed financial support to assist with analysis of blood samples and to further the AIBL research program. The Alzheimer's Association (USA) has contributed support to allow AIBL neuroimaging stream data (and accompanying clinical and cognitive data) to be made available via the Alzheimer's Disease Neuroimaging Initiative website. We thank Alzheimer's Australia (Victoria and Western Australia) who have assisted with promotion of the study and screening of telephone calls from volunteers, and collaborated with AIBL volunteer functions. Cassandra Szoeke is partially supported by a research fellowship funded by Alzheimer's Australia. The AIBL team wishes to thank all those who took part as subjects in the study for their commitment and dedication to helping advance research into the early detection and causation of AD.Cassandra Szoeke has received honoraria, to 2009, from Pfizer and Lundbeck and, to 2006, from Sanofi-Aventis and Mayne Pharma. David Ames has received remuneration for board membership of Pfizer, Novartis and Janssen-Cilag, and travel expenses from Novartis (2009).